Alfacell nears complete enrollment for phase 3 trial of Onconase cancer drug

By Angela McDaniels

Seattle, Jan. 19 - Alfacell Corp. said more than 300 patients are now enrolled in the company's international phase 3b clinical trial of lead drug candidate Onconase (ranpirnase) for the treatment of malignant mesothelioma that cannot be removed through surgery.

The required number of patients for full enrollment is 316.

"In enrolling more than 300 patients, Alfacell is conducting one of the largest global unresectable malignant mesothelioma studies ever undertaken," chief executive officer Kuslima Shogen said in a company news release.

Malignant mesothelioma is a rare form of cancer in which malignant cells are found in the sac lining the chest, the lining of the abdominal cavity or the lining around the heart. It is often associated with asbestos exposure.

Alfacell is a biopharmaceutical company based in Bloomfield, N.J., that discovers, develops and commercializes novel therapeutics for cancer using its proprietary RNase technology platform.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.